Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.

ABSTRACT:

Objectives

The aim was to evaluate the efficacy, defined as achieving target serum urate <6.0 mg/dl, and safety of urate-lowering therapies (ULTs) for people with gout and chronic kidney disease (CKD) stages 3-5.

Methods

PubMed, The Cochrane Library and EMBASE were searched from 1 January 1959 to 31 January 2018 for studies that enrolled people with gout, who had an estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) of <60 ml/min and exposure to allopurinol, febuxostat, probenecid, benzbromarone, lesinurad or pegloticase. All study designs other than case reports were included, except for people on dialysis, for whom we did include case reports.

Results

There were 36 reports with an analysis of efficacy and/or safety based upon renal function:

SUBMITTER: Farquhar H 

PROVIDER: S-EPMC7819867 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature